Single User License
INR 134140
Site License
INR 268280
Corporate User License
INR 402420

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline Review, H1 2015

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline Review, H1 2015


  • Products Id :- GMDHC6271IDB
  • |
  • Pages: 141
  • |
  • February 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline Review, H1 2015', provides an overview of the Transitional Cell Cancer (Urothelial Cell Cancer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Transitional Cell Cancer (Urothelial Cell Cancer)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Transitional Cell Cancer (Urothelial Cell Cancer) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Transitional Cell Cancer (Urothelial Cell Cancer)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Transitional Cell Cancer (Urothelial Cell Cancer) Overview 8

Therapeutics Development 9

Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer)-Overview 9

Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer)-Comparative Analysis 10

Transitional Cell Cancer (Urothelial Cell Cancer)-Therapeutics under Development by Companies 11

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Transitional Cell Cancer (Urothelial Cell Cancer)-Products under Development by Companies 16

Transitional Cell Cancer (Urothelial Cell Cancer)-Companies Involved in Therapeutics Development 18

Altor BioScience Corporation 18

Astellas Pharma Inc. 19

AstraZeneca PLC 20

Boston Biomedical, Inc. 21

Corcept Therapeutics Incorporated 22

Eli Lilly and Company 23

Exelixis, Inc. 24

GlaxoSmithKline plc 25

Innate Therapeutics Limited 26

Merck & Co., Inc. 27

Merck KGaA 28

Mirati Therapeutics Inc. 29

Novartis AG 30

Pfizer Inc. 31

Sanofi 32

Sumitomo Dainippon Pharma Co., Ltd. 33

Teva Pharmaceutical Industries Limited 34

Transitional Cell Cancer (Urothelial Cell Cancer)-Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Target 36

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

ACP-196-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

AGS-15E-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

ALT-801-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

amrubicin hydrochloride-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

ASG-15ME-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

avelumab-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

AZD-4547-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

BBI-503-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

buparlisib hydrochloride-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

cabazitaxel-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

cabozantinib s-malate-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

CEP-11981-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

enfortumab vedotin-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

mifepristone-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

MIS-416-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

mocetinostat-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

palbociclib-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

pembrolizumab-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

ramucirumab-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

SAR-408701-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

SNX-5422-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

trametinib dimethyl sulfoxide-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

Transitional Cell Cancer (Urothelial Cell Cancer)-Recent Pipeline Updates 98

Transitional Cell Cancer (Urothelial Cell Cancer)-Dormant Projects 135

Transitional Cell Cancer (Urothelial Cell Cancer)-Discontinued Products 137

Transitional Cell Cancer (Urothelial Cell Cancer)-Product Development Milestones 138

Featured News & Press Releases 138

May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 138

Appendix 140

Methodology 140

Coverage 140

Secondary Research 140

Primary Research 140

Expert Panel Validation 140

Contact Us 140

Disclaimer 141

List of Tables

Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H1 2015 9

Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Development by Companies, H1 2015 (Contd..1) 17

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Altor BioScience Corporation, H1 2015 18

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Astellas Pharma Inc., H1 2015 19

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by AstraZeneca PLC, H1 2015 20

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Boston Biomedical, Inc., H1 2015 21

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Corcept Therapeutics Incorporated, H1 2015 22

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Eli Lilly and Company, H1 2015 23

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Exelixis, Inc., H1 2015 24

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by GlaxoSmithKline plc, H1 2015 25

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Innate Therapeutics Limited, H1 2015 26

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Merck & Co., Inc., H1 2015 27

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Merck KGaA, H1 2015 28

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Mirati Therapeutics Inc., H1 2015 29

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Novartis AG, H1 2015 30

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Pfizer Inc., H1 2015 31

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Sanofi, H1 2015 32

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 33

Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 34

Assessment by Monotherapy Products, H1 2015 35

Number of Products by Stage and Target, H1 2015 37

Number of Products by Stage and Mechanism of Action, H1 2015 40

Number of Products by Stage and Route of Administration, H1 2015 42

Number of Products by Stage and Molecule Type, H1 2015 44

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics-Recent Pipeline Updates, H1 2015 98

Transitional Cell Cancer (Urothelial Cell Cancer)-Dormant Projects, H1 2015 135

Transitional Cell Cancer (Urothelial Cell Cancer)-Dormant Projects (Contd..1), H1 2015 136

Transitional Cell Cancer (Urothelial Cell Cancer)-Discontinued Products, H1 2015 137

List of Figures

Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H1 2015 9

Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 14

Assessment by Monotherapy Products, H1 2015 35

Number of Products by Top 10 Targets, H1 2015 36

Number of Products by Stage and Top 10 Targets, H1 2015 36

Number of Products by Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Top 10 Routes of Administration, H1 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42

Number of Products by Top 10 Molecule Types, H1 2015 43

Number of Products by Stage and Top 10 Molecule Types, H1 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Altor BioScience Corporation

Astellas Pharma Inc.

AstraZeneca PLC

Boston Biomedical, Inc.

Corcept Therapeutics Incorporated

Eli Lilly and Company

Exelixis, Inc.

GlaxoSmithKline plc

Innate Therapeutics Limited

Merck & Co., Inc.

Merck KGaA

Mirati Therapeutics Inc.

Novartis AG

Pfizer Inc.

Sanofi

Sumitomo Dainippon Pharma Co., Ltd.

Teva Pharmaceutical Industries Limited

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutic Products under Development, Key Players in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Overview, Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline, Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com